Home

RAYMOND W COHEN

CIK 1258288 · Chief Executive Officer · last filed 2026-09-10

RAYMOND W COHEN is a Chief Executive Officer who has filed 79 SEC Form 4 insider transactions across 7 companies since 2008. The most recent filing, for KMTS, was dated Sep 10, 2026. Across all open-market trades the lifetime net is −$38.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.0M across reported positions. 12 SEC filings were submitted jointly with SPECTRUM PHARMACEUTICALS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$3.02M

Companies

7

Total Filings

79

Lifetime Open-Market Net

-$38.12M

Filer Profile

Reported Address
C/O KESTRA MEDICAL TECHNOLOGIES, LTD.
3933 LAKE WASHINGTON BLVD NE, SUITE 200
KIRKLAND, WA 98033
Related Filers
SPECTRUM PHARMACEUTICALS INC — 12 joint filings, latest 2019-06-21
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KMTS Director 58,120 $27.14 $1.58M $488.8K 4 2026-09-10
RXST Director 66,532 $4.66 $310.0K $0 2 2026-06-18
NSPR Director 92,417 $0.70 $64.7K $0 1 2026-01-16
Axonics, Inc. (AXNX) Delisted Chief Executive Officer 692,151 $70.98 $49.13M -$36.75M 27 2024-11-15
BLFS Director 27,763 $38.49 $1.07M -$1.69M 21 2021-07-14
SPECTRUM PHARMACEUTICALS INC (SPPI) Delisted Director 53,850 $1.03 $55.5K -$169.9K 11 2019-06-21
Cardiac Science CORP (CSCX) Delisted Director 13,825 — — $0 4 2009-05-27

Recent Filings

79 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-10 KMTS Grant (A) +7,217 $0 EDGAR
2026-08-18 RXST Notice (144) −11,890 -$75.7K EDGAR
2026-06-18 RXST Grant (A) +30,864 $0 EDGAR
2026-03-30 KMTS Buy (P) +10,000 $199.8K EDGAR
2026-01-16 NSPR Grant (A) +44,030 $0 EDGAR
2025-09-08 KMTS Mixed +27,909 $289.0K EDGAR
2025-08-04 RXST Grant (A) +35,668 $0 EDGAR
2025-07-24 KMTS Grant (A) +12,994 $0 EDGAR
2024-11-15 Axonics, Inc. (AXNX) Delisted Disp (D) −292,731 -$20.78M EDGAR
2024-07-25 Axonics, Inc. (AXNX) Delisted Exer (M) +103,896 $2.38M EDGAR
Showing 1–10 of 79
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.